Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (NASDAQ: CRVS) has released new interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial, which includes data from 26 patients across two cohorts, showed promising results with 26% of treated patients achieving IGA 0 or 1 and 37% achieving EASI 75, while no placebo patients reached these endpoints.
The study evaluated two dosing regimens: Cohort 1 with 100 mg twice daily (12 patients) and Cohort 2 with 200 mg once daily (7 patients), against placebo groups. All Cohort 2 patients completed the 28-day treatment period with no significant safety issues or laboratory abnormalities. The trial is designed to enroll 64 patients total across four cohorts, with full results expected in Q2 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 13-16, 2025. Richard A. Miller, M.D., the company's president and chief executive officer, will engage in one-on-one investor meetings and deliver a corporate overview presentation.
The presentation is scheduled for Wednesday, January 15, 2025, at 2:15 pm ET / 11:15 am PT. An audio webcast will be available live and accessible for 30 days after the event through the investor relations section of Corvus's website.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial's lowest dose cohort demonstrated favorable safety and efficacy profiles. Key findings include:
- Mean EASI score reduction of 55.9% at 28 days and 69.1% at 58 days in the treatment group, compared to 27.0% and 19.1% in placebo
- Nine of 12 patients achieved EASI 50 at day 28, with three achieving EASI 75 and one reaching EASI 90
- No significant safety issues were observed during the trial
Additionally, Samlyn Capital exercised warrants to purchase 3,633,978 shares, providing approximately $12.7 million in cash proceeds to Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will release interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024. The trial is a randomized, double-blind, placebo-controlled study evaluating the drug in patients with moderate to severe atopic dermatitis. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to present the data, which will also be released via press release. The presentation will include slides and be accessible through a toll-free domestic line or international dial-in, with a webcast replay available on the company's website for 60 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data for soquelitinib, their lead ITK inhibitor program, in npj Drug Discovery. The research demonstrates soquelitinib's potential as a novel approach to modulate tumor immunity through its mechanism of action - suppressing Th2 and Th17 cytokine production while sparing Th1 cytokines.
The data shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and enhances memory T cell function. The company is currently conducting a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic dermatitis, with plans to initiate another Phase 1 trial in solid tumors.
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib treatment, mice showed significant reduction in lung infiltration and fibrosis, improved clinical scores, reduced vascular smooth muscle hypertrophy, and lower right ventricular systolic blood pressure. These results were validated in a second bleomycin lung injury model.
Corvus Pharmaceuticals provided Q3 2024 updates on its clinical programs. The company is advancing two clinical trials for soquelitinib: a Phase 3 trial in Peripheral T Cell Lymphoma (PTCL) and a Phase 1 trial in atopic dermatitis, with interim data expected in December 2024. Financial highlights include cash position of $41.7M as of September 30, 2024, with an additional $5.9M from warrant exercises in October. Q3 net loss was $40.2M, including a $32.8M non-cash warrant liability loss. R&D expenses increased to $5.2M from $4.0M year-over-year. The company expects current cash to fund operations into 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP1+ myeloid cells as critical mediators of immunotherapy resistance. Clinical trial results showed that when ciforadenant was combined with atezolizumab, 5 of 24 patients (21%) achieved PSA partial responses, compared to 1 of 11 (9%) with ciforadenant monotherapy. The study demonstrated that ciforadenant treatment reduced immunosuppression and enhanced sensitivity to anti-PD1 therapy.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will host a conference call and webcast on November 12, 2024 at 4:30 pm ET to provide a business update and report third quarter 2024 financial results. The conference call can be accessed toll-free at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations section, with a replay accessible for 90 days on Corvus' website.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Soquelitinib, a potential first-in-class ITK inhibitor, has been granted Orphan Drug Designation and Fast Track Designation by the FDA. The trial will enroll approximately 150 patients across 40 sites in the US, Canada, Australia, and South Korea.
The randomized, controlled study will compare soquelitinib to standard chemotherapy, with a primary endpoint of progression-free survival. Soquelitinib's unique mechanism of action, based on selective ITK inhibition, shows potential for treating T cell lymphomas, solid tumors, and immune diseases. This trial marks a significant milestone for Corvus and PTCL patients, as there are currently no fully approved agents for relapsed PTCL treatment.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
